Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ado-P-Ch2-P-Ps-Ado is a synthetic small molecule and an experimental analog of dinucleoside polyphosphates. Structurally, it is a modified diadenosine triphosphate in which the central phosphate bridge contains a methylene group (CH₂) and one terminal phosphate is replaced by a thiophosphate (Ps). It has been studied primarily as a biochemical probe for enzymes with dinucleoside triphosphate hydrolase activity, such as those that cleave P(1)-P(3)-bis(5'-adenosyl) triphosphate (Ap₃A), yielding AMP and ADP. The compound can also be hydrolyzed by adenylylsulfatase activity to yield AMP and sulfate, or act as an adenosine 5'-monophosphoramidase substrate. Its main use is in enzymology research rather than clinical medicine[1][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ado-P-Ch2-P-Ps-Ado.